Vemurafenib Has Activity in Patients With BRAFV600-Mutant Glioma

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-rw2018-189
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-Treated Patients With BRAFV600-mutated Metastatic Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2019English

Mutant IDH1 and Seizures in Patients With Glioma

Neurology
Neurology
2017English

Camrelizumab Has Activity in Patients With Nasopharyngeal Carcinoma

Cancer Discovery
Oncology
2018English

Parsaclisib Has Activity in Patients With B-Cell Malignancies

Cancer Discovery
Oncology
2019English

mTORC1/autophagy-regulated MerTK in Mutant BRAFV600 Melanoma With Acquired Resistance to BRAF Inhibition

Oncotarget
Oncology
2017English

Trabectedin Plus Olaparib Has Activity in Patients With Soft-Tissue Sarcoma

Cancer Discovery
Oncology
2018English

Liquid Biopsies in Patients With Diffuse Glioma

Acta Neuropathologica
Forensic MedicineMolecular NeurosciencePathologyNeurologyCellular
2015English

Toxicity Evaluation of Replication-Competent Herpes Simplex Virus (ICP 34.5 Null Mutant 1716) in Patients With Recurrent Malignant Glioma

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2000English

Seizures in Patients With Glioma Treated With Phenytoin and Levetiracetam

Journal of Neurosurgery
SurgeryNeurology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy